Sales growth remains strong with a 17% CAGR and FY26 revenue at $255 million NZD. Regulatory progress and a robust R&D pipeline support the $300 million FY27 revenue target, with new product launches and global trials underway.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.